Oric Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that address mechanisms of therapeutic resistance in cancer. The company targets innate, acquired, and bypass resistance to overcome limitations in existing cancer treatments, with a particular emphasis on hormone-dependent cancers, key tumor dependencies, and precision oncology. Its lead clinical-stage product candidates include rinzimetostat (ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 under investigation in Phase 1b studies for metastatic castration-resistant prostate cancer, often in combination with androgen receptor inhibitors, and enozertinib (ORIC-114), a brain-penetrant, orally bioavailable irreversible inhibitor targeting EGFR exon 20 insertion mutations, atypical EGFR mutations including PACC, and HER2 exon 20 mutations in non-small cell lung cancer patients, demonstrating systemic and central nervous system activity. Oric Pharmaceuticals Inc. maintains ongoing Phase 1b trials for these candidates, either as monotherapy or in combinations, and holds clinical development collaborations with partners such as Pfizer, Bayer, and Johnson & Johnson. Founded in 2014 and headquartered in South San Francisco, California, the company plays a significant role in advancing oncology innovations against resistance challenges.